PET of Brain Amyloid and Tau in Mild Cognitive Impairment

Department of Psychiatry and Biobehavioural Sciences, University of California, Los Angeles, Los Ángeles, California, United States
New England Journal of Medicine (Impact Factor: 54.42). 12/2006; 355(25):2652-63. DOI: 10.1056/NEJMoa054625
Source: PubMed

ABSTRACT Amyloid senile plaques and tau neurofibrillary tangles are neuropathological hallmarks of Alzheimer's disease that accumulate in the cortical regions of the brain in persons with mild cognitive impairment who are at risk for Alzheimer's disease. Noninvasive methods to detect these abnormal proteins are potentially useful in developing surrogate markers for drug discovery and diagnostics.
We enrolled 83 volunteers with self-reported memory problems who had undergone neurologic and psychiatric evaluation and positron-emission tomography (PET). On the basis of cognitive testing, 25 volunteers were classified as having Alzheimer's disease, 28 as having mild cognitive impairment, and 30 as having no cognitive impairment (healthy controls). PET was performed after injection of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), a molecule that binds to plaques and tangles in vitro. All subjects also underwent 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET, and 72 underwent magnetic resonance imaging (MRI).
Global values for FDDNP-PET binding (average of the values for the temporal, parietal, posterior cingulate, and frontal regions) were lower in the control group than in the group with mild cognitive impairment (P<0.001), and the values for binding in the group with mild cognitive impairment were lower than in the group with Alzheimer's disease (P<0.001). FDDNP-PET binding differentiated among the diagnostic groups better than did metabolism on FDG-PET or volume on MRI.
FDDNP-PET scanning can differentiate persons with mild cognitive impairment from those with Alzheimer's disease and those with no cognitive impairment. This technique is potentially useful as a noninvasive method to determine regional cerebral patterns of amyloid plaques and tau neurofibrillary tangles.

Download full-text


Available from: Helen Lavretsky, Jul 30, 2015
  • Source
    • "The establishment of aMCI biomarkers would be of benefit to clinicians as the biomarkers could be used as objective diagnostic tools, thus allowing early or pre-symptomatic identification of AD, aiding treatment decisions, monitoring disease progress, and providing opportunities for prevention by population screening (Henry et al., 2012). The methods used to search for biomarkers of MCI include neuroimaging techniques (Small et al., 2006; Hämäläinen et al., 2007), cerebrospinal fluid analysis (Perneczky et al., 2011), genetic analysis (Zhang et al., 2012) and electroencephalography (EEG), both quantitative EEG (see Jackson and Snyder, 2008) and event-related potentials (ERPs; see Jackson and Snyder, 2008 and Vecchio and Määttä, 2011). The use of ERP technique in the search for aMCI biomarkers is founded on three essential characteristics designated as ideal (see Hampel et al., 2010): it is non-invasive, simple to measure and inexpensive. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It has been suggested that changes in some event-related potential (ERP) parameters associated with controlled processing of stimuli could be used as biomarkers of amnestic mild cognitive impairment (aMCI). However, data regarding the suitability of ERP components associated with automatic and involuntary processing of stimuli for this purpose are not conclusive. In the present study, we studied the Mismatch Negativity (MMN) component, a correlate of the automatic detection of changes in the acoustic environment, in healthy adults and adults with aMCI (age range: 50-87 years). An auditory-visual attention-distraction task, in two evaluations separated by an interval of between 18 and 24 months, was used. In both evaluations, the MMN amplitude was significantly smaller in the aMCI adults than in the control adults. In the first evaluation, such differences were observed for the subgroup of adults between 50 and 64 years of age, but not for the subgroup of 65 years and over. In the aMCI adults, the MMN amplitude was significantly smaller in the second evaluation than in the first evaluation, but no significant changes were observed in the control adult group. The MMN amplitude was found to be a sensitive and specific biomarker of aMCI, in both the first and second evaluation.
    Frontiers in Aging Neuroscience 12/2013; 5:79. DOI:10.3389/fnagi.2013.00079 · 2.84 Impact Factor
  • Source
    • "In this way, the first successful radiotracer for amyloid imaging of AD patients was [ 18 F]- FDDNP (2-(1-{6-[(2-[F]Fluoroethyl)(methyl)amino]-2-naphthyl} ethylidene)malononitrile) which binds to hyperphosphorylated tau aggregates as well (Shoghi-Jadid et al., 2002). AD patients showed an increase of 10%e20% in the tracer binding in the affected brain regions compared with control subjects (Burggren et al., 2006). The next radiotracer developed was [ 11 C]-PIB (Pittsburg compound B) which does not bind to hyperphosphorylated tau aggregates but presents a higher specific binding to amyloid aggregates in comparison with [ 18 F]-FDDNP (Klunk et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography (PET) has been used extensively to evaluate the neuropathology of Alzheimer's disease (AD) in vivo. Radiotracers directed toward the amyloid deposition such as [(18)F]-FDDNP (2-(1-{6-[(2-[F]Fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile) and [(11)C]-PIB (Pittsburg compound B) have shown exceptional value in animal models and AD patients. Previously, the glucose analogue [(18)F]-FDG (2-[(18)F]fluorodeoxyglucose) allowed researchers and clinicians to evaluate the brain glucose consumption and proved its utility for the early diagnosis and the monitoring of the progression of AD. Animal models of AD are based on the transgenic expression of different human mutant genes linked to familial AD. The novel transgenic 5XFAD mouse containing 5 mutated genes in its genome has been proposed as an AD model with rapid and massive cerebral amyloid deposition. PET studies performed with animal-dedicated scanners indicate that PET with amyloid-targeted radiotracers can detect the pathological amyloid deposition in transgenic mice and rats. However, in other studies no differences were found between transgenic mice and their wild type littermates. We sought to investigate in 5XFAD mice if the radiotracers [(11)C]-PIB, and [(18)F]-Florbetapir could quantify the amyloid deposition in vivo and if [(18)F]-FDG could do so with regard to glucose consumption. We found that 5XFAD animals presented higher cerebral binding of [(18)F]-Florbetapir, [(11)C]-PIB, and [(18)F]-FDG. These results support the use of amyloid PET radiotracers for the evaluation of AD animal models. Probably, the increased uptake observed with [(18)F]-FDG is a consequence of glial activation that occurs in 5XFAD mice.
    Neurobiology of aging 02/2013; 34(7). DOI:10.1016/j.neurobiolaging.2012.12.027 · 4.85 Impact Factor
  • Source
    • "Nonparametric Wilcoxon two-sample tests within MCI and cognitively normal groups separately found no significant differences in regional FDDNP signals between the two PET scanners (p values ranging from 0.18 to 0.84). FDDNP-PET binding levels were quantified as previously described [37]. Briefly, we performed Logan graphical analysis with cerebellum as the reference region for time points between 30 and 125 minutes [44]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The relationship of cerebrovascular risk and Alzheimer's disease (AD) pathology to cognition in pre-dementia has been extensively investigated and is well-established. Cerebrovascular risk can be measured using a Framingham Stroke Risk Profile (FSRP) score, while positron emission tomography (PET) scans with 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP) measure AD neuropathology (i.e., amyloid-β plaques and tau tangles). Here we report results of 75 healthy non-demented subjects (mean age, 63 years) who underwent neuropsychological testing, physical assessments, and FDDNP-PET scans. Controlling for AD family history, education, and APOE4 status in a general linear model, higher FSRP risk and global FDDNP-PET binding were each associated with poorer cognitive functioning. The interaction of FSRP and global FDDNP-PET binding was not significant in the model, indicating that stroke risk and plaque and tangle burden each contributed to worse cognitive performance. Within our healthy volunteers, age, blood pressure, and antihypertensive medication use were vascular risks that contributed significantly to the above findings. These findings suggest that even mild cerebrovascular risk may influence the extent of cognitive dysfunction in pre-dementia, along with amyloid-β and tau burden.
    Journal of Alzheimer's disease: JAD 02/2013; 35(1). DOI:10.3233/JAD-121903 · 4.15 Impact Factor
Show more